European heart journal. Cardiovascular Imaging · 2025
Late gadolinium enhancement dispersion for predicting malignant arrhythmic events in patient with non-ischaemic dilated cardiomyopathy.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Aquaro Giovanni Donato, Merlo Marco, Barison Andrea, De Luca Antonio, Restivo Luca, Licordari Roberto, Todiere Giancarlo, Grigoratos Crysanthos, Faggioni Lorenzo, Cioni Dania, Di Bella Gianluca, Lencioni Riccardo, Emdin Michele, Neri Emanuele, Sinagra Gianfranco
Аннотация
AIMS: Arrhythmic risk stratification in patients with non-ischaemic dilated cardiomyopathy (DCM) remains challenging. The LGE-dispersion mapping is a novel method for the quantification of tissue heterogeneity through the Global Dispersion Score (GDS). We sought to evaluate the usefulness of GDS in arrhythmic risk stratification of DCM patients.
METHODS AND RESULTS: Consecutive non-ischaemic DCM patients underwent cardiac magnetic resonance imaging. GDS was calculated in LGE images. During a follow-up of 3.3 years (2 to 6 years), the combined endpoint of sudden cardiac death and appropriate implantable cardioverter-defibrillator intervention was considered. The final population included 510 patients (mean age was 56 ± 15 years). Left ventricular ejection fraction (LVEF) was >35% in 241 patients (47%). LGE was present in 225 patients (45%). Median extent of LGE was 12% of LV mass [interquartile range (IQR) 6-20%]. Among patients with positive LGE, GDS was 0.14 (IQR 0.08-0.20). During follow-up 81 patients had malignant ventricular arrhythmias (8 SCD, 73 appropriate ICD interventions). At Kaplan-Meier analysis, patients with GDS > 0.10 had worse prognosis than those with lower values of GDS (P < 0.0001). At multivariate analysis, GDS > 0.10 (HR 2.9, 95% CI: 1.7-5, P = 0.0002) was an independent predictor of events. The prognostic value of GDS was confirmed in subgroups of patients with LVEF ≤ 35% and >35%.
CONCLUSION: GDS is a useful marker to identify DCM patients at higher risk for malignant arrhythmic events regardless of LVEF and extent of LGE.
METHODS AND RESULTS: Consecutive non-ischaemic DCM patients underwent cardiac magnetic resonance imaging. GDS was calculated in LGE images. During a follow-up of 3.3 years (2 to 6 years), the combined endpoint of sudden cardiac death and appropriate implantable cardioverter-defibrillator intervention was considered. The final population included 510 patients (mean age was 56 ± 15 years). Left ventricular ejection fraction (LVEF) was >35% in 241 patients (47%). LGE was present in 225 patients (45%). Median extent of LGE was 12% of LV mass [interquartile range (IQR) 6-20%]. Among patients with positive LGE, GDS was 0.14 (IQR 0.08-0.20). During follow-up 81 patients had malignant ventricular arrhythmias (8 SCD, 73 appropriate ICD interventions). At Kaplan-Meier analysis, patients with GDS > 0.10 had worse prognosis than those with lower values of GDS (P < 0.0001). At multivariate analysis, GDS > 0.10 (HR 2.9, 95% CI: 1.7-5, P = 0.0002) was an independent predictor of events. The prognostic value of GDS was confirmed in subgroups of patients with LVEF ≤ 35% and >35%.
CONCLUSION: GDS is a useful marker to identify DCM patients at higher risk for malignant arrhythmic events regardless of LVEF and extent of LGE.